Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 370 versus VARIBAR NECTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 370 versus VARIBAR NECTAR.
ULTRAVIST 370 vs VARIBAR NECTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated non-ionic contrast agent that attenuates X-rays due to its high iodine content (370 mg I/mL), enhancing vascular and tissue contrast during imaging. Does not bind to plasma proteins and has minimal pharmacological effects.
Barium sulfate is a radiopaque contrast agent that coats the mucosal surface of the gastrointestinal tract, allowing radiographic visualization of anatomical structures by attenuating X-rays.
Adult: IV administration of 370 mg iodine/mL at 1-1.5 mL/kg (370-555 mg I/kg) for CT; up to 300 mL total. Rate: 1-5 mL/sec.
For radiographic examination of the esophagus, stomach, and duodenum: 30-90 mL of a 40-70% w/v barium sulfate suspension administered orally. For double-contrast studies, 100-200 mL of a 250% w/v suspension may be used. Route: oral. Frequency: single dose prior to imaging.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged to up to 36 hours in severe renal impairment (CrCl <30 mL/min).
Not applicable as Varibar Nectar is not systemically absorbed. The elimination half-life from the GI tract is approximately 4-6 hours, corresponding to the transit time through the small and large intestine. This is not a terminal half-life in the classic pharmacokinetic sense.
Renal: 95% unchanged within 24 hours via glomerular filtration; Biliary/Fecal: <5%; negligible biliary excretion.
Varibar Nectar is a barium sulfate suspension used as a radiographic contrast agent. It is not absorbed systemically and is eliminated entirely via the gastrointestinal tract. Following oral administration, the majority (~95-100%) is excreted unchanged in the feces within 24-72 hours. Minimal renal excretion (<1%) occurs only if absorbed, which is negligible in patients with intact GI mucosa.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent